News
SOTIO to Present Data Highlighting Progress Across ADC and Immunocytokine Programs at Upcoming Scientific Conferences
SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, today announced it will present new preclinical and translational data from multiple investigational programs at two scientific conferences in November – the World ADC Conference in San Diego, California, and PEGS Europe, in Lisbon, Portugal.
SOTIO Exercises Option for Novel Antibody-Drug Conjugate Program under Agreement with LegoChem Biosciences
- SOT106 is an antibody-drug conjugate (ADC) targeting an attractive surface antigen expressed on multiple solid tumors.
- Preclinical efficacy and tolerability studies of SOT106 show promising results across multiple solid tumor indications and a beneficial therapeutic index.
- SOTIO is actively exploring additional tumor targets to expand the collaboration with LegoChem Biosciences to up to five ADC programs.
SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, today announced that it has exercised its first of five exclusive, target-specific options with LegoChem Biosciences (LCB, KOSDAQ: 141080) for antibody-drug conjugate (ADC) SOT106, which is currently being evaluated in preclinical studies across a multitude of solid tumor indications.
SOTIO Biotech B.V.
Zuidplein 168
1077 XV Amsterdam
Netherlands
Zuidplein 168
1077 XV Amsterdam
Netherlands
SOTIO Biotech a.s.
Českomoravská 2532/19b
190 00 Prague 9
Czech Republic
Českomoravská 2532/19b
190 00 Prague 9
Czech Republic
SOTIO Biotech AG
Lichtstrasse 35 - WSJ-210
4056 Basel
Switzerland
Lichtstrasse 35 - WSJ-210
4056 Basel
Switzerland
SOTIO Biotech Inc.
180 Canal St., Suite 300
Boston, MA 02114
USA
180 Canal St., Suite 300
Boston, MA 02114
USA
